Mercedes K. Meyer, Ph.D. collaborates with her life sciences clients from start-up to Fortune 500 companies on their patent portfolio strategy and manages an extensive biotechnology and pharmaceutical patent prosecution practice. She drafts, prosecutes, opines and oversees global patent portfolio management, development, investment and acquisition. She works with Boards of Directors on start-ups for innovation monetization. She has experience in due diligence, patent interferences, reexamination, litigation, drug pricing and bioethics issues.
With a Ph.D. in virology and A.B. in chemistry, Mercedes has an intimate understanding of complex biotechnology and chemical subjects and their interplay. She helps clients protect innovations in areas covering antibodies, enzymes, viral vectors, genomics, vaccines, stem cell research, gene therapy, drug screening and identification, protein and tissue arrays, cancer therapeutics, cancer diagnostics, X-ray protein crystallography, food and beverages, animal health products, and industrial enzymes for biofuels and cosmetics. Her doctoral background provides practical research experience in the area of retroviruses, including HIV-1, virology, molecular biology, cancer biology, immunology and protein chemistry.
Mercedes is Co-Chair of the firm’s Intellectual Property Life Sciences Team, and an active member of the American Intellectual Property Law Association (AIPLA), the Intellectual Property Owner’s Organization (IPO) and Federal Circuit Bar Association (FCBA). She co-authored Patent Ethics – Prosecution (20016, 4th ed.) with David Hricik for LexisNexis.
- Provides frequent joint party representation to protect collaborative works between corporations and universities.
- Has obtained patent term extension on several patents under 35 USC 156.
- Successfully cancelled claims in third party reexamination.
- Regularly performs due diligence and white space analysis in fields such as antibodies, medical devices, and vaccines.
- Frequent speaker on ethics issues including on professionalism, mental health, and conflicts of interest.
- Speaks frequently on the Alice, Myriad, and Prometheus decisions and blogs regularly about their impact on innovation in the United States.
IAM Patent 1000, Intellectual Asset Management (2012 – 2016)
IP Stars Top 250 Women in IP, Managing Intellectual Property (2013 – 2014)
Fellow, American Intellectual Property Law Association
Awards Methodology (www.drinkerbiddle.com/content/awards)
Vice Chair of the IPO Women in IP Committee (2016 IPO Outstanding Committee of the Year Award Winner),
Co-Chair of the Diversity Committee of FCBA
Patent Ethics: Prosecution
- District of Columbia
- U.S. Patent and Trademark Office
- University of Houston, J.D., 1996
- University of Texas, Ph.D., Virology, 1994
- Bryn Mawr College, B.A., Chemistry, 1988
- American Intellectual Property Law Association (AIPLA), Board of Directors
- IPO, Vice Chair Women in IP (2016)
- Federal Circuit Bar Assn., Co-Chair, Diversity (2015-Present)
- AIPLA, Biotechnology Committee, (Past Vice Chair 2007 – 2009)
- AIPLA, Women in IP Law Committee, (Past Chair 2005 – 2007)